Si-Bone Stock Soared Almost 20%: Key Drivers This Week
Si-Bone stock soared almost 20% on Tuesday as investors reacted to strong quarterly results and optimistic guidance. ...
Healthcare Stocks
This tag page curates 5 Healthcare Stocks articles to help you assess risks, dividend potential, and notable moves from Chemed to UnitedHealth, helping smarter investment decisions.
85 articlesHarrow (HROW) 2026 Earnings: Key Takeaways for Investors
Harrow Health's Q1 2026 earnings transcript offers more than numbers—it reveals management's execution plan and what ...
Pfizer Buy, Sell, Hold: 2026 Stock Outlook and Strategy
Pfizer faced a post-pandemic revenue shift, but the 2026 landscape still offers income and defensive upside. This gui...
Hims Hims 2026 Earnings: Q1 Insights for Investors
An investor's guide to the early signals from hims 2026 earnings. We break down Q1 results, margins, and what they me...
Intuitive Surgical's Moat Getting Stronger: Forever Stock?
In healthcare robotics, durable moats matter as much as dazzling tech. This article breaks down why intuitive surgica...
Pfizer Stock: Still Priced — a Long-Term Opportunity for Investors
Pfizer's stock has lagged since 2021, but the story isn’t over. This guide breaks down why pfizer stock: still priced...
Why UnitedHealth Group Stock Came Roaring Back in April
April brought a notable rebound for UnitedHealth Group Stock. This article breaks down the earnings, margin improveme...
Why LifeStance Health Group Zoomed 20% Higher Today
LifeStance Health Group stunned the market with a beat-and-raise quarter, sending its stock up roughly 20%. This deep...
Pfizer's 6.5% Dividend Yield: Skepticism Silenced Now
A high dividend can spark doubt. This article breaks down pfizer's 6.5% dividend yield, what it signals about the bus...
Viemed (VMD) 2026 Earnings Outlook for Investors Today
Explore Viemed's 2026 earnings outlook with a practical, numbers-driven view. Learn the key drivers, risks, and how t...
Two Stocks Plan Hold Next: 20-Year Hold Picks for Growth
If you’re building a retirement roadmap, long-horizon stock bets can compound your wealth. Here are two healthcare-fo...
Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...